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Other names: IBD2; SEL1-like 
Location: 14q24.3-q31 
Local order: SEL1L is located within a 'Gene Desert 
area' or 'Genome Deserts'; centromeric to FLRT2 
(fibronectin leucine rich transmembrane protein 2) and 
telomeric to GTF2A1 (general transcription factor IIA) 
and TSHRq31 (thyroid stimulating hormone receptor). 
Note: SEL1L is the human ortholog of the C.Elegans  
sel-1 (suppressor enhancer of lin-12) gene. It show a 
high degree of cross-species conservation in its 
nucleotide and protein sequence. 
DNA/RNA 
Description 
SEL1L genomic size is of 62,24 Kb localized from 
81069886 to 81007646. 3’ the first exon lies the basal 
core of the promter, a TATA-less promoter containing 
four SP1 binding sites and a CAAT box. A CpG island  
 
 
A graphical representation of SEL1L isorforms. The black numbered rectangles correspond to the exons, while the white rectangles 
correspond to the intronic sequence which is retained in the alternative isoforms. The SEL1L domains are indicated on the top of the 
isoforms. (FN2=fibronectin type II domain; I, II and III clusters of SEL-1 like repeats; Hrd3; TM=transmembrane; P= proline rich domain). 
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is located between -550bp and the start codon. SEL1L 
embryonic kidney cells. The C-terminal tail consist of 
over 5,0Kb untranslated sequences likely containing 
key regulatory elements. 
Transcription 
The sequence is composed of 21 exons and produces at 
least five different alternative transcripts (A-E) which 
originate from alternative splicing and putative 
promoter usage. Exons 1-6 are common to forms A-B-
C-E. 
Pseudogene 
No known pseudogenes 
Protein 
Note: SEL1L is a multimodular protein consisting of 
several domains and signal sequences that confer the 
multifaceted specificities to the molecule. 
Description 
SEL1L is not a member of a vast family of proteins but
the several described isoforms (over 4) give the 
appearance of belonging to a multifamily of moleculs 
having perhaps redundant functions. 
Expression 
Ubiquitously expressed only in fetal and neoplastic 
tissues. In normal adult tissues is highly expressed in 
the acini and in the alpha cells of the pancreas; in 
general is highly represented in secretory cells such as 
plasma cells. 
Localisation 




May have a role in the ER-associated protein 
degradation (ERAD) system (similarity with Hrd3). 
Negative regulator of the NOTCH pathway in C. 
Elegans. 
May play a role in TGF beta signalling. 
In breast and pancreatic tumor decrease tumor growth 
and aggressiveness, possibly involving cell-matrix 
interaction. 
Homology 
Comparative sequence analysis across different regna, 
including metazoa, fungi, viridiplantae and bacteria, 
revealed the remarkable conservation of its primary 
sequence, although the gene structural complexity 
increased in evolution. Among mammals, SEL1L 
shares strict amino acid identity with chimpanzee 
(99%), dog (97%), hamster (92%), mouse (93%) and 
rat (92%). It also shows a good similarity with the 
model organisms such as xenopus (82%), chicken 
(83%), zebrafish (73%), Drosophila melanogaster 
(51%) and C. elegans (46%) (Table 1). Arabidopsis 
thaliana and Saccharomyces cerevisiae display lower 
similarity (34% and 28%, respectively). 
Mutations 
Note: Neither causative nor functional mutations were 
found except for the presence of two base substitutions 
in the minimal promoter region in two well 
differentiated lung adenocarcinoma that led to a 
significant increase in the transcription. A polymorphic 
base substitution was reported in the fibronectin type II 
domain of the gene in children affected by persistent 
hyperinsulinemic hypoglycemia (insulinoma) of 





SEL1L protein structure: SEL1L is a multimodular protein containing several structural and functional domains as well as signal 
sequences. The signal peptide (from 1 to 22 amino acid residues) and the Pest sequence (from 80 to 102 amino acid residues) are 
represented by red and pink rectangles. The fibronectin type II domain (from 120 to 168 residues) is symbolized by the hexagon (FNII), 
the SEL-1-like repeats are represented by rhombi and are distributed in tandem along the central portion of the protein in three large 
clusters (I cluster: 183-326; II cluster: 373-554 and III cluster: 664-675 residues). The Hrd3 like motif is located within the last SEL-1-like 
repeat (664-675 residues) and is represented by an circle. The transmembrane region (TM) (739-761 residues) and the proline-rich tail 
(770-793 residues) are symbolized by a blue rectangle. The N-linked glycosilation is also underlined. 
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Implicated in 
Considering the overall results published on SEL1L by 
various investigators working in different organisms, it 
can, perhaps, safely be deduced that this gene plays a 
fundamental role in eukaryotic intracellular protein 
degradation processes. Protein degradation is becoming 
a central theme in cancer biology and recently 
therapeutic approaches that use inhibitors of proteins 
belonging to ubiquitin-proteosoma pathway have been 
developed in solid tumors and haematological diseases. 
A survey of the expression of SEL1L mRNA as well as 
its encoded protein on a series of cancerous and pre-
neoplastic lesion, revealed the role of SEL1L in cacer 
progression. Furthermore, its expression in breast 
cancer correlated with patient¹s survival. In vitro 
studies indicated that SEL1L protein affects those 
pathways which regulate signalling (cell-cell and or 
cell-matrix) interactions. Available data derived from 
several organisms indicate that it may function in the
protein degradation processes through ubiquitin-
proteosome system and perhaps in regulating important 
pathways such as Notch and TGF-beta. The 
fundamental question raised by the observation that
SEL1L gets up-modulated during the early steps of 
tumor transformation is of paramount importance for 
early diagnosis. Currently it is only possible to 
hypothesize that the increased SEL1L levels are 
required in order to meet the advent of genetic and/or 
genomic structural alterations acquired during cancer 
initiation or to influence intra-cellular signalling. Its 
presence may be important in protecting cellular 
homeostasis from genetic mutations. 
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